Bristol Myers Squibb (BMS) has announced a major collaboration and licensing agreement with China-based Hengrui Pharma. The deal covers 13 early-stage research programs with a potential total value of $15.2 billion, marking one of the most significant international pharmaceutical partnerships of 2026.
Financial structure and payment timeline Under the agreed terms, BMS will pay Hengrui a total of $950 million through 2028, consisting of:
-
An upfront payment of $600 million.
-
$175 million on the first anniversary of the closing.
-
A $175 million contingent payment in 2028. The remaining portion of the $15.2 billion valuation includes option fees and milestone payments tied to development, regulatory approval, and commercial performance.
A three-track collaborative strategy The partnership is structured across three main product categories, all currently in the pre-clinical stage (prior to human trials):
-
4 candidates from Hengrui: Focused on oncology and hematology; BMS holds exclusive rights outside mainland China, Hong Kong, and Macau.
-
4 compounds from BMS: Focused on immunology; Hengrui will lead exploitation within the Chinese market, while BMS retains commercial rights elsewhere.
-
5 joint programs: Both companies will collaborate on discovery and development of new therapeutic candidates.
Leveraging local speed and expertise Across all 13 programs, Hengrui will be responsible for early clinical development and proof-of-concept work. This strategy allows BMS to capitalize on China’s rapid clinical trial environment to quickly gather insights and make informed decisions to drive growth over the next decade.
The transaction is expected to close in the third quarter of 2026, subject to regulatory reviews under the Hart-Scott-Rodino Antitrust Improvements Act.
Source: https://qz.com/bristol-myers-squibb-hengrui-pharma-licensing-deal-051226